首页> 美国卫生研究院文献>BMC Cancer >Poker association of weekly alternating 5-fluorouracil irinotecan bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

【2h】

Poker association of weekly alternating 5-fluorouracil irinotecan bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

机译：每周交替使用5-氟尿嘧啶伊立替康贝伐单抗和奥沙利铂（FIr-B / FOx）的扑克协会在转移性结直肠癌的一线治疗中：II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThis phase II study investigated efficacy and safety of weekly alternating Bevacizumab (BEV)/Irinotecan (CPT-11) or Oxaliplatin (OHP) associated to weekly 5-Fluorouracil (5-FU) in first line treatment of metastatic colorectal carcinoma (MCRC).

机译：背景这项II期研究调查了每周一次贝伐单抗（BEV）/伊立替康（CPT-11）或奥沙利铂（OHP）与每周5-氟尿嘧啶（5-FU）联合治疗转移性大肠癌（MCRC）的有效性和安全性。

著录项

期刊名称 BMC Cancer
作者
Gemma Bruera; Alessandra Santomaggio; Katia Cannita; Paola Lanfiuti Baldi; Marianna Tudini; Federica De Galitiis; Maria Mancini; Paolo Marchetti; Adelmo Antonucci; Corrado Ficorella; Enrico Ricevuto;
展开▼
作者单位

展开▼
年(卷),期 2010(10),-1
年度 2010
页码 567
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study [J] . Gemma Bruera, Alessandra Santomaggio, Katia Cannita, BMC Cancer . 2010,第1期

机译：每周交替使用5-氟尿嘧啶，伊立替康，贝伐单抗和奥沙利铂（FIr-B / FOx）的“扑克”协会在转移性结直肠癌的一线治疗中：II期研究
2. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies [J] . Iwasa Satoru, Nagashima Kengo, Yamaguchi Tatsuro, Cancer chemotherapy and pharmacology. . 2015,第3期

机译：S-1和伊立替康联合或不联合贝伐单抗与5-氟尿嘧啶和亚叶酸加奥沙利铂联合或不联合贝伐单抗治疗转移性结直肠癌的四项II期研究的汇总分析
3. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) [J] . J Souglakos, N Androulakis, K Syrigos, British Journal of Cancer . 2006,第6期

机译：FOLFOXIRI（亚叶酸，5-氟尿嘧啶，奥沙利铂和伊立替康）与FOLFIRI（亚叶酸，5-氟尿嘧啶和伊立替康）作为转移性结直肠癌（MCC）的一线治疗：来自希腊肿瘤研究组的多中心随机III期试验（霍格）
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Rationale and design of the TRUSTY study: a randomised multicentre open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy [O] . Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, 2018

机译：TRUSTY研究的原理和设计：三氟哌啶/替匹西酯加贝伐单抗与伊立替康氟嘧啶+贝伐单抗作为二线治疗的转移性结直肠癌患者在第一期或之后进展的随机多中心II / III期开放性研究基于奥沙利铂的化疗
6. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study [O] . Gemma Bruera, Alessandra Santomaggio, Katia Cannita, 2010

机译：每周交替使用5-氟尿嘧啶，伊立替康，贝伐单抗和奥沙利铂（FIr-B / FOx）的“扑克”协会在转移性结直肠癌的一线治疗中：II期研究

Poker association of weekly alternating 5-fluorouracil irinotecan bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

摘要

著录项

相似文献

相关主题

期刊订阅